CaP Biomaterials expands Wisconsin facility as it marks 20 years

By AI, Created 12:01 PM UTC, June 02, 2026, /AGP/ – CaP Biomaterials said it is expanding its East Troy, Wisconsin site as the calcium phosphate manufacturer marks its 20th anniversary. The investment adds lab space, analytical equipment and calcium sulfate production as the company pushes to deepen its role as a U.S.-based contract manufacturing partner for medical device OEMs.

Why it matters: - CaP Biomaterials is betting that medical device OEMs want more U.S.-based supply, larger manufacturing capacity and a lower-risk contract partner for calcium phosphate materials. - The expansion strengthens a supplier that already supports programs from early R&D through commercial production. - The move also adds calcium sulfate to the company’s biomaterials portfolio, broadening options for orthopedic, spine, dental, trauma and soft-tissue implant applications.

What happened: - CaP Biomaterials announced a further expansion of its East Troy, Wisconsin manufacturing facility as the company marked its 20th anniversary. - The investment doubles laboratory space and adds new analytical equipment. - The company also expanded its biomaterials portfolio to include calcium sulfate. - CaP operates a 20,000-plus-square-foot facility under an ISO 13485:2016-certified quality management system. - The company supports medical device OEMs with batch sizes up to 600 kg.

The details: - CaP was founded in 2006 after a medical device manufacturer sought a U.S. source of synthetic hydroxyapatite and could not find one. - Dr. Larry Shimp founded the company after that need emerged, drawing on decades of calcium phosphate and biomaterials experience. - Dr. Larry Shimp and Dr. Bill Hubbard co-founded the company and built its scientific base around calcium phosphate and bone substitute technologies. - Dr. Shimp remains CTO and founder. - TESco Associates, Inc. acquired majority ownership in 2019 and has since accelerated investment in infrastructure, quality systems, personnel and manufacturing capabilities. - CaP produces hydroxyapatite, tricalcium phosphate, biphasic calcium phosphate and custom biomaterial formulations. - The company says it does not develop finished medical devices, compete with customer products or participate in customer distribution channels. - CaP’s commercial focus is custom calcium phosphate materials and processes for OEM co-development and manufacturing. - The company says its relationships with orthopedic and medical device companies have gone through supplier qualification, quality system audits, process validation and technical reviews. - Many of those relationships have become multi-year supply agreements. - Onno Visser, site manager at CaP Biomaterials, said the company is a “no-nonsense contract manufacturing company” focused on meeting customer needs.

Between the lines: - The expansion signals that CaP is positioning itself as a primary supplier rather than just a backup source for OEMs. - The company is leaning into a model that separates it from device makers, which can matter for customers that want a manufacturing partner, not a competitor. - The investment in lab capacity and analytics suggests CaP is targeting more technical development work, not just higher-volume production. - In a market where overseas sourcing can add supply-chain risk, CaP is pitching domestic manufacturing, ISO certification and scale as the differentiators.

What’s next: - CaP will exhibit at OMTEC 2026 in Chicago on June 11-12 at Booth 1213. - The company plans to discuss co-development programs, supplier qualification, facility expansion details and material sampling for active device projects. - Interested companies can schedule a meeting with Keith Orlowski, sales director, at korlowski@capbiomaterials.com or visit more information.